PRAGUE MEDICAL REPORT
PRAGUE MEDICAL REPORT
Prague Medical Report is an English quarterly published multidisciplinary biomedical journal. Prague Medical Report was founded as Sborník lékařský in May 1885. The journal presents public primary scientific publications, short communications, casuistry, and reviews. It contains articles based on important specialised lectures and symposia.

PRAGUE MEDICAL REPORT, Vol 122 No 4 (2021), 243–256

Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients

Jaroslava Roušarová, Martin Šíma, Ondřej Slanař

DOI: https://doi.org/10.14712/23362936.2021.22
published online: 20. 12. 2021

abstract

Protein kinase inhibitors (PKIs) represent up-to-date therapeutic approach in breast cancer treatment. Although cancer is a rapidly progressive disease, many substances, including PKIs, are usually used at fixed doses without regard to each patient’s individuality. Therapeutic drug monitoring (TDM) is a tool that allows individualization of therapy based on drug plasma levels. For TDM conduct, exposure-response relationships of drug substances are required. The pharmacokinetic data and exposure-response evidence supporting the use of TDM for 6 PKIs used in breast cancer treatment, one of the most common female tumour diseases, are discussed in this review.

keywords: Abemaciclib; Everolimus; Lapatinib; Neratinib; Palbociclib; Ribociclib

Creative Commons License
Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients is licensed under a Creative Commons Attribution 4.0 International License.

167 x 240 mm
periodicity: 4 x per year
print price: 450 czk
ISSN: 1214-6994
E-ISSN: 2336-2936

Download